Master Merial Venture Agreement, dated as of May 23, 1997 (Exhibit 10.4) (1997)

Government Record · Rhone-Poulenc S.A., Institut Merieux S.A., Rhone-Merieux S.A., Merck & Co., Inc., Merck SH Inc., Merial Limited · May 23, 1997

Rhone-Poulenc S.A. et al., 1997-05-23: The contract that created Merial as a 50/50 Merck / Rhone-Poulenc animal-health venture, with ancillary licence and supply agreements.

RP and Merck wish to combine their respective Animal Health Businesses and Poultry Genetics Businesses into a worldwide venture owned and controlled 50% by each of them

Rhone-Poulenc S.A. et al., 1997-05-23: The contract that created Merial as a 50/50 Merck / Rhone-Poulenc animal-health venture, with ancillary licence and supply agreements. F3/F4. Filing exhibit, US federal record (public domain), HTML on EDGAR, hence LINK. Records that the venture was 'owned and controlled 50% by each of them' and that the parties would enter into 'Ancillary Agreements, including research and development, manufacturing and supply, license and various other agreements'. This is the document that moved the ivermectin animal-health brands (Ivomec, Heartgard) out of Merck alone and into a jointly owned company. No royalty rate is stated in the excerpted recitals.